Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PMX63 (brilacidin) is a de novo-designed synthetic, non-peptidic, small molecule that kills pathogens swiftly, greatly reducing the likelihood of drug resistance developing. It also functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing.
Lead Product(s): Brilacidin
Therapeutic Area: Infections and Infectious Diseases Product Name: PMX63
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
The new PMX63 (brilacidin) findings in fungal keratitis complement an earlier in vitro and in vivo evaluation of Brilacidin as an ocular anti-infective in bacterial keratitis.
Lead Product(s): Brilacidin
Therapeutic Area: Infections and Infectious Diseases Product Name: PMX63
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
In pre-clinical studies, PMX63 (brilacidin) shown to synergize with marketed antifungals against pathogenic species of aspergillosis, candidiasis, cryptococcosis and mucormycosis, and further exhibited potent stand-alone efficacy against Cryptococcus neoformans.
Lead Product(s): Brilacidin
Therapeutic Area: Infections and Infectious Diseases Product Name: PMX63
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
Innovation Pharmaceuticals remains optimistic about Brilacidin, even Phase 2 COVID-19 clinical trial did not meet its primary endpoint. Brilacidin a novel drug candidate proven to have antibiotic, anti-inflammatory and antiviral properties.
Lead Product(s): Brilacidin
Therapeutic Area: Infections and Infectious Diseases Product Name: PMX30063
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2021
Details:
Brilacidin, a defensin mimetic, with potential antimicrobial and anti-mucositic activities used in hospitalized patients with moderate-to-severe COVID-19. Brilacidin is being developed for treatment of COVID-19.
Lead Product(s): Brilacidin
Therapeutic Area: Infections and Infectious Diseases Product Name: PMX30063
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
Details:
Company has received confirmation that hard lock of the database was completed for its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients.
Lead Product(s): Brilacidin
Therapeutic Area: Infections and Infectious Diseases Product Name: PMX30063
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2021
Details:
Brilacidin has shown potent and consistent inhibition in vitro against coronaviruses, alphaviruses and bunyaviruses (with laboratory testing against other viruses also underway), supporting Brilacidin’s potential to be developed as a broad-spectrum antiviral.
Lead Product(s): Brilacidin
Therapeutic Area: Infections and Infectious Diseases Product Name: PMX30063
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
Based on pre-clinical studies, Brilacidin is exhibiting an ability to directly disrupt viral integrity, a potent virucidal property, enabling it to be unaffected by mutations that give rise to variants-a beneficial trait differentiating Brilacidin from other antivirals.
Lead Product(s): Brilacidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
Details:
Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.
Lead Product(s): Brilacidin
Therapeutic Area: Infections and Infectious Diseases Product Name: PMX30063
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2021
Details:
In Phase 2, ~120-patient, randomized, double-blind, placebo-controlled clinical trial evaluating Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients. Early in April, enrollment in the trial reached 25 percent.
Lead Product(s): Brilacidin
Therapeutic Area: Infections and Infectious Diseases Product Name: PMX30063
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021